Subscribe to RSS
Download PDF
DOI: 10.4103/ijmpo.ijmpo_313_20
Antibody Drug Conjugates
Financial support and sponsorship Nil.
Abstract
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released, which finally leads to cell killing. Payloads are broadly divided into tubulin-disrupting agents and DNA-damaging agents. Most of the current ADCs utilize humanized mAbs, and fully human mAbs are under investigation. ADC development process is accelerated by better designing and bio-engineering methods.
Publication History
Received: 29 June 2020
Accepted: 19 August 2020
Article published online:
14 May 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 356-india-fact-sheets.pdf. Available from: https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf. [Last accessed on 2020 Jun 03].
- 2 Census of India Website: Causes of Death Statistics. Available from: https://censusindia.gov.in/vital_statistics/causesofdeath.html. [Last accessed on 2020 May 23].
- 3 Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8: 473-80
- 4 Kanellos J, Pietersz GA, McKenzie IF. Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. JNCI J Natl Cancer Inst 1985; 75: 319-32
- 5 Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM. et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261: 212-5
- 6 Strohl WR. Current progress in innovative engineered antibodies. Protein Cell 2018; 9: 86-120
- 7 Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody–drug conjugates: A comprehensive review. Mol Cancer Res 2020; 18: 3-19
- 8 Hughes B. Antibody-drug conjugates for cancer: Poised to deliver?. Nat Rev Drug Discov 2010; 9: 665-7
- 9 Casi G, Neri D. Noninternalizing targeted cytotoxics for cancer therapy. Mol Pharm 2015; 12: 1880-4
- 10 Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ. et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 2008; 19: 759-65
- 11 Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 2018; 9: 33-46
- 12 Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy. J Cell Physiol 2018; 233: 6441-57
- 13 Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required? Br J Cancer 2017; 117: 1736-42
- 14 García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody-drug conjugates. Cancer Res 2018; 78: 2159-65